Home » Topics » Disease categories and therapies » Cardiovascular

Cardiovascular
RSS

Nonpeptide Y1 antagonist H-409/22 examined for in vivo effects on vascular responses

Oct. 19, 2000

AstraZeneca licenses antiarrhythmic drug candidate from Nortran

Oct. 19, 2000

Nortran's new ion channel blockers useful as antiarrhythmics

Oct. 18, 2000

Esperion acquires biotechnology company; LUV program proceeds ahead of schedule

Oct. 18, 2000

Potent Na+/H+ exchange inhibitor TY-12533 displays excellent cardioprotective profile in vivo

Oct. 18, 2000

Preliminary human safety and PK/PD findings reported for Z-13752A

Oct. 18, 2000

Second gene therapy product from Collateral advances to clinical testing

Oct. 16, 2000

Roche presents recently identified endothelin receptor antagonists

Oct. 13, 2000

PI-88's novel mechanism of action revealed; compound enters two new trials

Oct. 10, 2000

Natural compound improves hypertension

Oct. 9, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...